Recombinant Human KRAS G12V(HLA-A*03:01)(His-Avi Tag)

Description :
FAQ COA 已发表文献 Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. 产品性质 别名Synonyms MHC, KRAS, K-Ras 2, KRAS2, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KRAS1, KRAS2, NS, NS3, RASK2, GTPase Kras, KI-RAS, RALD Uniprot No. NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVGAVGVGK Source Recombinant Human KRAS G12V(HLA-A*03:01)Protein is expressed from HEK293Cellswith His tag and Avi tag at the C-terminal.It containsGly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide. 分子量(Molecular Weight) Approximately 50.2kDa.Due to glycosylation, the protein migrates to55-60kDa based on Tris-Bis PAGE result. 外观(Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 95% as determined by SDS-PAGEand HPLC Activity SPRData: Human KRAS G12V (HLA-A*03:01) Complex, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-KRAS G12V (HLA-A*03:01) Antibody with an affinity constant of 0.205M as determined in SPR assay (Biacore T200). 内毒素Endotoxin 1.0EU per 1g of the protein by the LAL method. Formulation Lyophilized from 0.22m filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization. 复溶Reconstitution Centrifuge tubes before opening. Reconstituting to a concentration more than 100 g/mL`is recommended (usually we use 1mg/mLsolution for lyophilization). Dissolve the lyophilized protein in distilled water.